# ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
Canonical URL: https://biopharmsignal.com/news/IBRX/immunitybio-presents-health-economic-analysis-at-ispor-2026-showing-anktivar-plus-bcg-delivers-lower-cost-per-sustained-complete-response-versus-tar-200-in-bcg-unresponsive-nmibc-cis
Ticker: IBRX
Company: ImmunityBio
Source: ImmunityBio
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.immunitybio.com
## Summary

Analysis demonstrates a lower cost per sustained responder and cystectomy avoided with ANKTIVA plus BCG compared to TAR-200 in Medicare population over three years CULVER CITY, Calif. --(BUSINESS WIRE)--May 22, 2026-- ImmunityBio, Inc. ( NASDAQ: IBRX), a commercial-stage immunotherapy company,

## Article Body
Analysis demonstrates a lower cost per sustained responder and cystectomy avoided with ANKTIVA plus BCG compared to TAR-200 in Medicare population over three years CULVER CITY, Calif. --(BUSINESS WIRE)--May 22, 2026-- ImmunityBio, Inc. ( NASDAQ: IBRX), a commercial-stage immunotherapy company,
## Recent Company News
- 2026-06-25 13:46 EST — [ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026](https://biopharmsignal.com/news/IBRX/immunitybio-presents-new-clinical-and-comparative-data-across-lung-and-bladder-cancer-at-asco-2026) — Source: ImmunityBio
- 2026-06-25 13:46 EST — [ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation](https://biopharmsignal.com/news/IBRX/immunitybio-highlights-patient-survey-data-at-ispor-2026-showing-majority-of-uk-adults-living-with-nmibc-favor-bladder-preservation) — Source: ImmunityBio
- 2026-06-25 13:46 EST — [ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS](https://biopharmsignal.com/news/IBRX/immunitybio-presents-health-economic-analysis-at-ispor-2026-showing-anktivar-plus-bcg-delivers-lower-cost-per-sustained-complete-response-versus-tar-200-in-bcg-unresponsive-nmibc-cis) — Source: ImmunityBio
- 2026-06-25 13:46 EST — [ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027](https://biopharmsignal.com/news/IBRX/immunitybio-announces-fda-acceptance-of-supplemental-bla-for-anktivar-plus-bcg-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-with-papillary-disease-pdufa-date-set-for-january-6-2027) — Source: ImmunityBio
- 2026-06-25 13:46 EST — [ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026](https://biopharmsignal.com/news/IBRX/immunitybio-presents-favorable-comparative-effectiveness-data-in-complete-response-rates-of-nai-bcg-versus-nadofaragene-and-tar-200-at-aua-2026) — Source: ImmunityBio
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)